Randomized, Open-Label, Daily Dose, 2-sequence, 2-way Crossover Pharmacodynamic and Pharmacokinetic Study of BiDil XR Capsules and Commercial BiDil Tablets in Self-identified Black Patients, Who Are Slow Acetylators, With Heart Failure

Trial Profile

Randomized, Open-Label, Daily Dose, 2-sequence, 2-way Crossover Pharmacodynamic and Pharmacokinetic Study of BiDil XR Capsules and Commercial BiDil Tablets in Self-identified Black Patients, Who Are Slow Acetylators, With Heart Failure

Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Nov 2016

At a glance

  • Drugs Hydralazine/isosorbide dinitrate (Primary)
  • Indications Heart failure
  • Focus Therapeutic Use
  • Sponsors Arbor Pharmaceuticals
  • Most Recent Events

    • 12 Jul 2016 Status changed from recruiting to completed.
    • 26 Apr 2016 Planned End Date changed from 1 Mar 2016 to 1 May 2016.
    • 26 Apr 2016 Planned primary completion date changed from 1 Mar 2016 to 1 May 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top